|
시장보고서
상품코드
2024426
폼페병 치료 시장 규모 : 치료법, 투여 경로, 유통 채널, 적응증 유형, 지역별(2026-2034년)Pompe Disease Treatment Market Size by Treatment, Route of Administration, Distribution Channel, Indication Type, and Region 2026-2034 |
||||||
세계의 폼페병 치료 시장 규모는 2025년에 11억 달러에 이르렀습니다. 향후, IMARC Group은 2034년까지 시장 규모가 14억 달러에 이르고, 2026-2034년 CAGR 2.37%를 나타낼 것으로 예측했습니다. 임상연구 증가와 효소대체요법(ERT)의 대중화가 진행되면서 시장 성장을 견인하고 있습니다.
폼페병은 글리코겐이라는 복합 당이 체내 세포에 축적되어 장기, 조직, 근육에 영향을 미치는 유전성 질환입니다. 리소좀 효소인 산성 알파-글루코시다아제(GAA)의 결핍으로 인해 발생하는 상염색체 열성 유전성 글리코겐 저장 증후군입니다. 이 질환은 근력저하, 간종대, 호흡곤란, 청력장애, 폐감염, 부정맥, 체중감소 등을 동반합니다. 진단에는 근전도, 엑스레이, 자기공명영상법(MRI) 등 다양한 검사와 방법이 사용됩니다. 폼페병 치료에는 약물요법, 효소대체요법(ERT), 기질감소요법(SRT), 샤페론강화대체요법(CART), 주사 등이 사용되며, 이는 삶의 질 향상에 기여합니다.
폼페병 치료 시장 동향 :
개인의 유전적 이상 유병률이 눈에 띄게 증가하고 있으며, 폼페병 환자 수도 증가하고 있습니다. 이와 더불어, 영아에서 폼페병 증가와 신생아 건강에 대한 부모들의 관심 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한, 이러한 질환에 걸리기 쉬운 고령 인구 증가로 인해 폼페병 치료에 대한 수요가 증가하고 있습니다. 또한, 폼페병의 새로운 치료법을 개발하기 위한 임상 연구와 임상시험 증가도 시장에 긍정적인 영향을 미치고 있습니다. 이와 더불어 폼페병 치료로서 효소대체요법(ERT)에 대한 인식이 높아진 것도 시장 성장에 힘을 보태고 있습니다. 또한, 줄기세포 이식, 골수 이식, 화학요법, 면역요법 등 다양한 치료법에 대한 인식이 높아지면서 그 많은 장점으로 인해 인지도가 높아지고 있습니다. 여기에 루미자임과 같은 ERT 치료의 대안이 쉽게 구할 수 있다는 인식이 더해져 시장 전망을 밝게 하고 있습니다. 이와 더불어, 폼페병 치료에 대한 경제적 지원을 제공하고 의료비를 최소화하는 건강 보험 가입이 증가하고 있습니다. 또한, 많은 국가의 정부 및 비정부기구(NGO)는 모든 사람이 이용할 수 있는 양질의 의료시설을 제공하기 위한 조치를 취하고 있습니다. 여기에 진단 기술의 눈부신 발전이 더해져 시장에 긍정적인 전망을 가져다 줄 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 폼페병 치료 시장 규모는 어느 정도인가요?
- 폼페병 치료 시장 전망은 어떻습니까?
- 폼페병 치료 시장을 이끄는 주요 요인은?
- 폼페병 치료 시장에서 가장 큰 점유율을 차지하는 지역은?
- 세계 폼페병 치료 시장의 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 폼페병 치료 시장
제6장 시장 분석 : 치료법별
제7장 시장 분석 : 투여 경로별
제8장 시장 분석 : 유통 채널별
제9장 시장 분석 : 적응증 유형별
제10장 시장 분석 : 지역별
제11장 성장 촉진요인, 억제요인 및 기회
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KTH 26.05.15The global Pompe disease treatment market size reached USD 1.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 1.4 Billion by 2034, exhibiting a growth rate (CAGR) of 2.37% during 2026-2034. The increasing number of clinical research and the growing popularity of enzyme replacement therapy (ERT) are stimulating the market.
Pompe disease is a genetic disorder caused by the buildup of a complex sugar known as glycogen in the cells of the body, which affects organs, tissues, and muscles. It is an autosomal recessive glycogen storage syndrome caused by the deficiency of lysosomal enzyme acid a-glucosidase (GAA). It is associated with weak muscles, enlarged liver, trouble breathing, hearing problem, lung infection, irregular heartbeat, and losing weight. It is diagnosed using various tools and tests, including electromyography, X-rays, and magnetic resonance imaging (MRI). Pompe disease can be treated using medications, enzyme replacement therapy (ERT), substrate reduction therapy (SRT), chaperone-advanced replacement therapy (CART), and injections, which aid in improving the quality of life.
Pompe Disease Treatment Market Trends:
There is a considerable rise in the prevalence of genetic abnormalities among individuals and an increase in the number of patients suffering from Pompe disease. This, coupled with the growing Pompe disease among infants and increasing concerns among parents about the health of their newborns, represents one of the key factors bolstering the growth of the market. Moreover, the growing geriatric population that is susceptible to developing these medical disorders is resulting in an increasing demand for Pompe disease treatment. In addition, the expanding number of clinical studies and trials to develop new treatments for Pompe disease is influencing the market positively. Apart from this, the rising awareness among people about ERT for curing Pompe disease is favoring the market growth. Furthermore, there is an increase in awareness about various treatments, including stem cell transplant, bone marrow transplantation, chemotherapy, and immunotherapy, on account of their numerous advantages. This, along with the awareness about the easy availability of ERT treatment alternatives like lumizyme, is creating a positive outlook for the market. Besides this, there is a rise in the adoption of health insurance policies that provide financial assistance and minimize healthcare expenditure for Pompe disease treatment. Additionally, governments and non-governmental organizations (NGOs) of numerous countries are undertaking measures to offer quality healthcare facilities that are accessible to all. This, along with significant improvements in the diagnostic technologies, is anticipated to provide a favorable outlook to the market.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the market, along with the market forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on treatment, route of administration, distribution channel, and indication type.
Treatment Insights:
- Enzyme Replacement Therapy (ERT)
- Substrate Reduction Therapy (SRT)
- Chaperone-Advanced Replacement Therapy (CART)
- Others
Route of Administration Insights:
- Oral
- Intravenous
- Others
Distribution Channel Insights:
- Hospital and Clinics Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Indication Type Insights:
- Infantile-Onset Pompe Disease (IOPD)
- Classic Infantile Form
- Non-Classic Infantile Form
- Late-Onset Pompe Disease (LOPD)
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for Pompe disease treatment. Some of the factors driving the North America Pompe disease treatment market included the growing awareness about various alternative treatments, increasing number of clinical studies and trials, and well-established healthcare facilities.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global Pompe disease treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics Inc., Audentes Therapeutics Inc. (Astellas US Holding Inc.), Oxyrane UK Limited, Sanofi S.A., Spark Therapeutics Inc, etc.
Key Questions Answered in This Report
- How big is the pompe disease treatment market?
- What is the future outlook of pompe disease treatment market?
- What are the key factors driving the pompe disease treatment market?
- Which region accounts for the largest pompe disease treatment market share?
- Which are the leading companies in the global pompe disease treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Pompe Disease Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment
- 6.1 Enzyme Replacement Therapy (ERT)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Substrate Reduction Therapy (SRT)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Chaperone-Advanced Replacement Therapy (CART)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital & Clinics Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Indication Type
- 9.1 Infantile-Onset Pompe Disease (IOPD)
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Classic Infantile Form
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Non-Classic Infantile Form
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Late-Onset Pompe Disease (LOPD)
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
- 11.1 Overview
- 11.2 Drivers
- 11.3 Restraints
- 11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Amicus Therapeutics Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Audentes Therapeutics Inc. (Astellas US Holding Inc.)
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Oxyrane UK Limited
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Sanofi S.A.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Spark Therapeutics Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.1 Amicus Therapeutics Inc.
